Predictors of virological outcomes after analytical interruption of antiretroviral therapy following immune interventions with HTI vaccines in early-treated people with HIV: a pooled analysis from the AELIX-002 and AELIX-003 clinical trials

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Randomized, placebo-controlled clinical trials (RCTs) incorporating analytical treatment interruptions (ATI) are the gold standard in HIV cure research. Two independent RCTs, AELIX-002 and AELIX-003, evaluated HTI immunogen-based vaccines alone or combined with the TLR7 agonist vesatolimod in 88 early-treated people with HIV. These trials individually demonstrated that higher levels of vaccine-induced HTI-specific T-cell responses were associated with extended time off antiretroviral therapy (ART). Here, we performed a pooled analyses of both RCTs using logistic regression and receiver operating characteristic analyses and identified an HTI-specific cutoff of 835 spot-forming cells/10(6) peripheral blood mononuclear cells as a predictor of delayed and slower viral rebound during ATI. This threshold distinguished participants who are likely to remain off ART for >12 weeks, with 58% sensitivity, 85% specificity, 75% positive predictive value and 73% negative predictive value. These findings may inform futility criteria before ATI start in future HTI-based trials.

Article activity feed